Impact of Treatment With Colistin on Mortality Bacteremia Multiresistant Acinetobacter Baumannii Sensitive Colistin in Patients Critical

NCT02573064 | Completed

• 1 other identifier: FCO-COL-2015-01
• Study Type: observational
• Target: 113
• Locations: 0 countries
• Sites: N/A

Brief Summary

The present study was designed to study the impact of empirical treatment with colistin empirical monotherapy and combined treatment with tigecycline and vancomycin on mortality of bacteremia Multiresistant Acinetobacter Baumannii . The main objective was to evaluate the efficacy of empirical treatment with colistin and combined targeted therapy. The different therapeutical interventions were administered following the routine clinical practice in the medical centre and the investigator did not assign specific interventions to the subjects of the study.

Conditions

Acinetobacter Infections

Outcome Measures

Primary Outcomes (1)

• All-cause 30-day mortality (crude).

  30 days

Secondary Outcomes (1)

• All-cause 14 day mortality (crude).

  14 days

Interventions

Colistin DRUG

Tigecycline DRUG

Vancomycin DRUG

Eligibility Criteria

• Age: 16 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Critical patients with monomicrobial bloodstream infections due to monoclonal antibodies were studied; specific criteria were applied for analysis of empirical therapy and targeted therapy (113 patients).

You may qualify if:

• Critics included patients ≥ 16 years with monomicrobial bloodstream infections by multiresistant acinetobacter baumannii to carbapenems and sensitive to colistin accompanied by systemic inflammatory response syndrome, provided they have received targeted treatment with colistin.

Sponsors & Collaborators

• Maimónides Biomedical Research Institute of Córdoba: lead

Related Publications (1)

• Amat T, Gutierrez-Pizarraya A, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Torre-Gimenez A, Garnacho-Montero J, Cisneros JM, Torre-Cisneros J. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2018 Jun;24(6):630-634. doi: 10.1016/j.cmi.2017.09.016. Epub 2017 Sep 29.

  PMID: 28970161 DERIVED

MeSH Terms

Conditions

Acinetobacter Infections

Interventions

Colistin; Tigecycline; Vancomycin

Condition Hierarchy (Ancestors)

Moraxellaceae Infections; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections

Intervention Hierarchy (Ancestors)

Polymyxins; Peptides, Cyclic; Macrocyclic Compounds; Polycyclic Compounds; Lipopeptides; Lipids; Antimicrobial Cationic Peptides; Peptides; Amino Acids, Peptides, and Proteins; Antimicrobial Peptides; Pore Forming Cytotoxic Proteins; Membrane Proteins; Proteins; Tetracyclines; Naphthacenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Glycopeptides; Glycoconjugates; Carbohydrates

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 28, 2015
• First Posted: October 9, 2015
• Study Start: January 1, 2010
• Primary Completion: December 1, 2012
• Last Updated: October 9, 2015

Record last verified: 2015-10